Location History:
- Gaithersburg, MD (US) (1998 - 2003)
- Sunnyvale, CA (US) (1999 - 2007)
- Mountain View, CA (US) (2003 - 2009)
Company Filing History:
Years Active: 1998-2009
Title: Innovations in Vascular Biology: The Contributions of Jing-Shan Hu
Introduction
Jing-Shan Hu, based in Mountain View, CA, is a prominent figure in the field of biomedical research. With a remarkable portfolio that includes 24 patents, he has made significant strides in advancing our understanding of vascular biology and therapeutic interventions.
Latest Patents
Among Hu's latest innovations are his patents regarding antibodies to human vascular endothelial growth factor 2 (VEGF2) and the methods for utilizing these antibodies. His work encompasses the disclosure of a human VEGF2 polypeptide and the DNA/RNA encoding for such polypeptides. This includes a detailed procedure for producing these polypeptides through recombinant techniques. The therapeutic applications of these innovations are vast, including methodologies for stimulating wound healing and vascular tissue repair. Additionally, Hu has developed methods that use antagonists of VEGF2 to inhibit tumor growth, reduce inflammation, and treat conditions such as diabetic retinopathy, rheumatoid arthritis, and psoriasis. His diagnostic methods also allow for the detection of mutations in the VEGF2 coding sequence, promoting advancements in personalized medicine.
Career Highlights
Jing-Shan Hu has made a profound impact during his tenure at Human Genome Sciences, Inc. His continuous research work reflects his commitment to improving diagnostic and therapeutic strategies in the medical field. His extensive patent portfolio showcases his innovative mindset and dedication to harnessing biotechnology for healthcare improvements.
Collaborations
Throughout his career, Hu has collaborated with esteemed colleagues, including Craig A. Rosen and Liang Cao. These collaborations highlight his ability to work synergistically with other experts in the field to drive forward groundbreaking discoveries in vascular biology.
Conclusion
Jing-Shan Hu's contributions to the field of vascular research are noteworthy. His innovations, particularly in the realm of VEGF2, stand as a testament to his expertise and commitment to advancing healthcare. With 24 patents, Hu continues to exemplify the spirit of innovation, driving forward the boundaries of science and medicine.